Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is off-topic but watching the video at the 35:45 mark made me think of this.
Last year in September, a TV series titled Utopia came out on Amazon Prime Video. It was canceled after 1 season. The basis of the series was…
1. To convince the world's population of an outbreak of a deadly new virus.
2. Once convinced of the fake pandemic, announce to the public the creation of a new vaccine.
3. Through the coordination between global elites and non-governmental organizations, governments would move quickly to vaccinate the world's population with this vaccine.
4. Once the population is vaccinated, it turns out that the vaccine is designed to sterilize almost all of those people that take it, causing the global population to drop from 7.8 billion to about 500 million, and ushering in a new era of plenty.
This is an American TV Series which was adapted from a British TV Series of the same name which came out in the UK between 2013-2014. It ran for 2 seasons.
An excerpt from the British Series season 1, episode 5, February 12, 2013.
“The group attempt to extract information from their new hostage, Letts, who reveals that The Network plans to use the vaccine for the Russian flu as a vector for 'Janus,' a engineered virus that will sterilize 95% of the human race, in order to avert an impending overpopulation catastrophe.”
Yep. 33 Sites now.
Dr. Orvil Martínez-Rivera
San Juan, Puerto Rico, 00926
https://clinicaltrials.gov/ct2/show/NCT04504734
I'm not sure what affect this will have on Revive's Bucillamine.
Need to read the entire article to see the big picture.
WHO Celebrates As Indian Health Regulator Removes Ivermectin From Its COVID-19 Protocol
https://www.zerohedge.com/covid-19/who-celebrates-indian-health-regulator-removes-ivermectin-its-covid-19-protocol
Two more sites added as well. A total of 29, now.
HealthStar Research LLC
Hot Springs, Arkansas, United States, 71913
Physicians Quality Care
Jackson, Tennessee, United States, 38305
Congratulations on your wealth. No doubt it was acquired on the backs of your followers who were, most likely, left holding the bag. The last one's in ARE the one's holding the bag.
So, if you have no scruples...
40:55
The compelling story here from an investor perspective is there's really no company in the world that's in a Phase 3 that's worth less than,....right now, eight hundred - a billion. So, you get the best of both worlds with Revive. You have a psychedelic company, one of the top five, and a Phase 3 in Bucillamine. It sets us apart and i'd like, obviously, investors to recognize that.
Revive Therapeutics, Emerging Growth Conference 4/14/21
It's probably not going to happen but it would be great of the company to record the call and then provide for a playback of it on their website.
You left out this part of the filing...(intentionally?)
On January 11, 2019, Sun Pacific Holding Corp., a Nevada corporation (the “Company”)
SNPW is the Company
Two more sites added.
Entrust Clinical Research
Kendall, Florida, United States, 33156
American Clinical Trials LLC
Acworth, Georgia, United States, 30101
A total of 17.
https://clinicaltrials.gov/ct2/show/NCT04504734
One more site added at clinicaltrials.gov.
Monroe Biomedical Research
Monroe, North Carolina, United States, 28112
https://clinicaltrials.gov/ct2/show/NCT04504734
Here's a long but good read.
Pyrolysis: An effective technique for degradation of COVID-19 medical wastes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901847/
Let's Go.
I never stated that it did. I was simply asking for your thoughts on questions related to the solar side of SNPW.
So, what if the sun didn't come out tomorrow? What if the sun never came out again? How would it impact the solar side of SNPW? Is this something we should concern ourselves with?
Your thoughts? Your wisdom is appreciated.
What if the sun didn't come out tomorrow? What if the sun never came out again? How would it impact the solar side of SNPW? Is this something we should concern ourselves with?
Your thoughts?
Here's another test that has nothing to do with DECN's scam Genviro test.
March 26, 2021 4:07 AM
Britain gives go-ahead to 20-second COVID-19 test, distributor says
LONDON (Reuters) -A 20-second COVID-19 test will launch in Britain after regulators accepted its registration, the product’s distributor said on Friday, heralding a testing system it said could be used in airports, sports venues and businesses.
Rapid tests are seen as a key plank of Prime Minister Boris Johnson’s roadmap out of lockdown, but concerns have been expressed about the accuracy of existing lateral flow devices.
The Virolens test, which is made by British start-up iAbra and TT Electronics, has been piloted at Heathrow Airport, and uses swabs of saliva.
Histate, which is distributing the test, said it would launch with immediate effect after the Medicines and Healthcare products Regulatory Agency (MHRA) accepted the registration of the product, and the company said it was hoping for a wider rollout in coming months.
The MHRA does not issue approvals for COVID-19 tests in the way it does for vaccines, having determined they are effective, but registers medical devices with a certification mark if they meet legal criteria, are safe and are made to the standard specified by the manufacturer for the stated purpose.
Histate said trials had indicated the test had 98.1% sensitivity, meaning it returns few false negatives, and 99.7% specificity, meaning few false positives.
https://www.reuters.com/article/us-health-coronavirus-britain-20second/britain-approves-20-second-covid-19-test-distributor-says-idUSKBN2BI16V
Do you feel there's not much positive reasons to become a shareholder or to remain as one?
Could you give some of your insight to the positives that SNPW brings?
Here's an article from earlier this month that mentions his buys.
https://equity.guru/2021/03/05/revive-rvv-cn-ceo-michael-frank-likes-the-stock-buys-the-dip/
Why would anyone continue to buy this stock? The CEO has been charged with fraud. The last official press release from the Company was on December 21, 2020.
VANCOUVER, BC, March 9, 2021 /CNW/ - The following issues have been halted by IIROC:
Company: Revive Therapeutics Ltd.
CSE Symbol: RVV
All Issues: No
Reason: Single-Stock Circuit Breaker
Halt Time (ET): 10:14:03 AM
Shareholder Meeting info. Meeting to be held on April 12, 2021.
What could be driving today’s volume/PPS?
A (soon to be released) Canaccord Genuity report?
A possible agreement from the FDA for the Company to file for an EUA? (“the Company aims to approach the FDA to obtain agreement on filing an Emergency Use Authorization (“EUA”) for Bucillamine…”)
An expansion of the clinical sites from 14 to…?
Any other reasonable thoughts?
Also, how good does Michael Frank’s recently bought shares look now? And, if today’s action is indicative of pending (good) news from the Company then could Michael Frank’s open market purchase be perceived as buying on insider knowledge?
Revive Therapeutics Corporate Presentation for March 2021.
https://revivethera.com/wp-content/uploads/2021/03/RVV-Deck-March-2021-v1.pdf
If he was on par to some of us, say an 'open market purchase' of 436,000 shares, that to me would show confidence.
If your post was specifically directed at me then please allow me to explain my definition of what I view as transparency.
First of all, my first email to the Company (Michael Frank) was on October 1, 2020. Per the Company’s August 19, 2020 Press Release they were planning to expand the clinical trials to the Asia-Pacific countries and Canada. My email simply inquired if plans were still in place for the Company to expand the trials to these areas. Disappointedly, i received no response and i personally viewed his non-response as simply wanting to avoid answering “no” to my question, since to this day the Company still has not expanded the trials to these areas.
Per the Company’s Press Release on December 23, 2020 it was stated that they were on pace for the interim analysis on the first 210 patients. Between January 25, 2021 to January 28, 2021 I sent the Company (Michael Frank) 5 emails, simply looking for actual clarification that the 210 patients threshold had been achieved. I also inquired that if the threshold had been achieved if the DSMB were in the process of reviewing the data. My view was that these were simple questions that could be answered which would not be construed as the Company providing insider knowledge. My first 4 emails received no response until i sent a revised 5th email.
Michael Frank’s response…
((“It’s a Phase 3 double blinded study
Do you understand what that is ?
As you see on clinicaltrials.gov the study is progressing well and progressing
Thank you for your support
That’s all that can be said now”))
I understand that the clinical trial is a double blinded study. I understand that the Company can’t give me a response as to how the trial is proceeding, data wise (good or bad). I wasn’t inquiring about that. The transparency I was alluding to was simply for the Company to give a better, actual clarification on something that, imo, they had vaguely commented on. Michael Frank’s response, imo, did not provide that transparency.
Let me just say that I believe in the science of Bucillamine. I hope my email on February 9, 2021 had some impact which eventually persuaded the Company to put out today’s Press Release. I like this transparency.
It is my hope that the email i sent to the Company (Michael Frank) today persuades them to issue a Press Release of "transparency" regarding an update on their Phase 3 clinical trial.
From the same Short Form Prospectus...
Notes
"(1) The $9,000,000 is anticipated to be allocated to cover the following milestones and activities for the Bucillamine Phase 3 clinical study for COVID-19: (i) completion of the 210 patient interim analysis which is expected to be completed in Q1-2021"
This might explain the 5 million shares bought earlier today. Did the buyer know of the pending 8-K and it's information before it was filed?
Another email i've sent to Michael Frank. I finally got a reply. (Honestly, i don't care if it looks like i'm being pushy.)
Mr. Michael Frank,
Over the past few days I’ve sent multiple emails inquiring about the status of the completion of the first 210 patient enrollment, mainly if the enrollment of the first 210 patients has been met.
Reiterated -
((In a Press Release on October 25, 2020 the Company stated that, “it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020”.
In a Press Release on December 23, 2020 the Company stated that, “the Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization”.
We’re now in the latter part of January 2021. Has the 210 patients threshold been met? If so, is the DSMB now in the process of reviewing the data and will the Company publicly release the results?))
I understand a person in your position is probably extremely busy. However, it does not exactly instill shareholder confidence to have emails that go unanswered. If you’re unable to provide any meaningful answers at this time a simple reply of “no comment” would certainly go a long way than no reply at all.
Thank you,
xxxxx xxxxxxxxx
Revive Therapeutics Shareholder
His reply...
On Jan 28, 2021, at 3:44 PM, Michael Frank
<mfrank@revivethera.com> wrote:
It’s a Phase 3 double blinded study
Do you understand what that is ?
As you see on clinicaltrials.gov the study is progressing well and progressing
Thank you for your support
That’s all that can be said now
Michael Frank
CEO
Revive Therapeutics Inc.
Same here. I'm not selling what i've accumulated over the past 7 months. At some point the run in the other stocks will end and they will come crashing back down to their pre-run levels, imo. There will be bag holders.
The market is down. Also, because of the craziness happening in Gamestop, AMC Entertainment Holdings, Nokia, etc. (Look at Nokia. Their average volume is 42 million. Today they did over 1 billion in volume.)
People are selling other stocks to get into them. People are selling other stocks to cover their short positions in the above stocks, imo.
Look at MindMed, Red Light Holland, and Numinus Wellness. They're all down just as much as RVVTF.
For what it's worth, i emailed Michael Frank yesterday & today with a few simple questions. I haven't received a response back. Maybe he can't answer my questions or he doesn't like me. :(
Sent Mon, Jan 25 at 3:44 PM & Tue, Jan 26 at 9:58 AM
"Mr. Michael Frank,
In a Press Release on October 25, 2020 the Company stated that, “it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020”.
In a Press Release on December 23, 2020 the Company stated that, “the Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization”.
We’re now in the latter part of January 2021. Has the 210 patients threshold been met? If so, is the DSMB now in the process of reviewing the data and will the Company publicly release the results?
Thank you,
xxxxx xxxxxxxxx
Revive Therapeutics Shareholder"
History of changes - side by side comparison.
https://clinicaltrials.gov/ct2/history/NCT04504734?A=11&B=12&C=Side-by-Side#StudyPageTop
It's Estimated Primary Completion Date : July 2021
It's Estimated Study Completion Date : September 2021
Yep, too late.
I hadn't looked into it at the time of my posting but i believe you're right after looking at other none related stocks.